Pseudomonas Aeruginosa Treatment

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Antibiotic resistance in European wastewater treatment plants mirrors the pattern of clinical antibiotic resistance prevalence    Science Advances Integrated antibiotic resistance (AR) surveillance is one of the objectives of the World Health Organization global action plan on antimicrobial resistance.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Antibiotic resistance in European wastewater treatment plants mirrors the pattern of clinical antibiotic resistance prevalence    Science Advances Integrated antibiotic resistance (AR) surveillance is one of the objectives of the World Health Organization global action plan on antimicrobial resistance.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting    BioSpace MALVERN, Pa.--(BUSINESS WIRE)-- VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present during the ...

Antibiotic-resistant Bacteria (Superbugs) May Kill 10 Million People by 2050    Interesting Engineering Antibiotic-resistant bacteria, called superbugs, might kill 10 million people by 2050 if science doesn't respond quickly to the urgent need of developing new ...

Lying Is Good for My Health    Cystic Fibrosis News Today Columnist Bailey Anne Vincent ponders the frustrations and blessings of "lying" in her dance, health discussions, and self-identity.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    P&T Community FRAMINGHAM, Mass., March 27, 2019 /PRNewswire/ -- Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Microbes that live in fishes' slimy mucus coating could lead chemists to new antibiotic drugs    The Conversation US One day in the future, you may take a pill to treat an illness – and owe your recovery to the tiny microbes that flourish in the slippery layer of mucus that coats ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    P&T Community FRAMINGHAM, Mass., March 27, 2019 /PRNewswire/ -- Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting    BioSpace MALVERN, Pa.--(BUSINESS WIRE)-- VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present during the ...

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Fish slime: An untapped source of potential new antibiotics    Phys.Org As current antibiotics dwindle in effectiveness against multidrug-resistant pathogens, researchers are seeking potential replacements in some unlikely places.

Fish slime: An untapped source of potential new antibiotics    Phys.Org As current antibiotics dwindle in effectiveness against multidrug-resistant pathogens, researchers are seeking potential replacements in some unlikely places.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    P&T Community FRAMINGHAM, Mass., March 27, 2019 /PRNewswire/ -- Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Genotypic characterisation of Pseudomonas aeruginosa isolates from Tur | IDR    Dove Medical Press Genotypic characterisation of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis Dicle Sener Okur,1 Caner Yuruyen,2 Ozge Gungor,2 ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Antibiotic-resistant Bacteria (Superbugs) May Kill 10 Million People by 2050    Interesting Engineering Antibiotic-resistant bacteria, called superbugs, might kill 10 million people by 2050 if science doesn't respond quickly to the urgent need of developing new ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Final Results London Stock Exchange:SUMM    GlobeNewswire Summit Therapeutics plc ('Summit', the 'Company' or the 'Group'). Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended ...

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Antibiotic resistance in European wastewater treatment plants mirrors the pattern of clinical antibiotic resistance prevalence    Science Advances Integrated antibiotic resistance (AR) surveillance is one of the objectives of the World Health Organization global action plan on antimicrobial resistance.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Antibiotic resistance in European wastewater treatment plants mirrors the pattern of clinical antibiotic resistance prevalence    Science Advances Integrated antibiotic resistance (AR) surveillance is one of the objectives of the World Health Organization global action plan on antimicrobial resistance.

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

What is Keratocele?    News-Medical.net A keratocele, or descemetocele, is a herniation (perforation) of the Descemet membrane through the overlying corneal epithelium and supporting stroma.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    P&T Community FRAMINGHAM, Mass., March 27, 2019 /PRNewswire/ -- Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief ...

Antibiotic-resistant Bacteria (Superbugs) May Kill 10 Million People by 2050    Interesting Engineering Antibiotic-resistant bacteria, called superbugs, might kill 10 million people by 2050 if science doesn't respond quickly to the urgent need of developing new ...

Microbes that live in fishes' slimy mucus coating could lead chemists to new antibiotic drugs    The Conversation US As antibiotic resistance increases globally, the heat is on to find new alternatives to treat infections. Chemists can get a head start by looking at compounds ...

Fish slime: An untapped source of potential new antibiotics    EurekAlert As current antibiotics dwindle in effectiveness against multidrug-resistant pathogens, researchers are seeking potential replacements in some unlikely places.

Antibiotic-resistant Bacteria (Superbugs) May Kill 10 Million People by 2050    Interesting Engineering Antibiotic-resistant bacteria, called superbugs, might kill 10 million people by 2050 if science doesn't respond quickly to the urgent need of developing new ...

Lying Is Good for My Health    Cystic Fibrosis News Today Columnist Bailey Anne Vincent ponders the frustrations and blessings of "lying" in her dance, health discussions, and self-identity.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

Microbes that live in fishes' slimy mucus coating could lead chemists to new antibiotic drugs    The Conversation US As antibiotic resistance increases globally, the heat is on to find new alternatives to treat infections. Chemists can get a head start by looking at compounds ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Genotypic characterisation of Pseudomonas aeruginosa isolates from Tur | IDR    Dove Medical Press Genotypic characterisation of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis Dicle Sener Okur,1 Caner Yuruyen,2 Ozge Gungor,2 ...

Microbes that live in fishes' slimy mucus coating could lead chemists to new antibiotic drugs    SFGate (The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Sandra Loesgen, Oregon State ...

Final Results    Nasdaq Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress. Focus on.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Aridis Pharmaceuticals poised for readout of top-line data for its flagship AR-105 treatment in 3Q    Proactive Investors USA & Canada Aridis Pharmaceuticals Inc (NASDAQ:ARDS) - AR-105 is a treatment for ventilator-associated pneumonia caused by a variety of Pseudomonas aeruginosa, ...

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal    Nasdaq GAITHERSBURG, Md., March 28, 2019-- OpGen, Inc. announced today that data supporting prediction of antibiotic resistance using the company' s.

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Antibiotic-resistant Bacteria (Superbugs) May Kill 10 Million People by 2050    Interesting Engineering Antibiotic-resistant bacteria, called superbugs, might kill 10 million people by 2050 if science doesn't respond quickly to the urgent need of developing new ...

Lying Is Good for My Health    Cystic Fibrosis News Today Columnist Bailey Anne Vincent ponders the frustrations and blessings of "lying" in her dance, health discussions, and self-identity.

Aridis Pharmaceuticals poised for readout of top-line data for its flagship AR-105 treatment in 3Q    Proactive Investors USA & Canada Aridis Pharmaceuticals Inc (NASDAQ:ARDS) - AR-105 is a treatment for ventilator-associated pneumonia caused by a variety of Pseudomonas aeruginosa, ...

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal    Nasdaq GAITHERSBURG, Md., March 28, 2019-- OpGen, Inc. announced today that data supporting prediction of antibiotic resistance using the company' s.

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    GuruFocus.com Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update, Stocks: NAS:ARDS, release date:Mar 28, 2019.

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update    P&T Community SAN JOSE, Calif., March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and ...

Aridis Pharmaceuticals poised for readout of top-line data for its flagship AR-105 treatment in 3Q    Proactive Investors USA & Canada Aridis Pharmaceuticals Inc (NASDAQ:ARDS) - AR-105 is a treatment for ventilator-associated pneumonia caused by a variety of Pseudomonas aeruginosa, ...

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal    Nasdaq GAITHERSBURG, Md., March 28, 2019-- OpGen, Inc. announced today that data supporting prediction of antibiotic resistance using the company' s.

Global Non-antibiotic Bacterial Therapeutics Industry 2019-2024: Market Dynamics, Technologies and Company Profiles    PRNewswire DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Markets Non-antibiotic Bacterial Therapeutics" report has been added to ResearchAndMarkets.com's ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Viruses act as decoys, helping bacteria evade the immune system    STAT Not only has the team chronicled a strange case of collusion between viruses and bacteria, they've made a vaccine that may combat a dangerous pathogen.

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    P&T Community FRAMINGHAM, Mass., March 27, 2019 /PRNewswire/ -- Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief ...

Big Money Sentiment Indicator of Horizon Pharma Inc (NASDAQ:HZNP) Improves in Q4 2018 to 1.33    K Reviewer “Big money sentiment for Horizon Pharma Inc (NASDAQ:HZNP) in Q4 2018 increased to 1.33, SEC filings reveal. So its up 0.47, from 2018Q3's 0.86. 116 active ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Genotypic characterisation of Pseudomonas aeruginosa isolates from Tur | IDR    Dove Medical Press Genotypic characterisation of Pseudomonas aeruginosa isolates from Turkish children with cystic fibrosis Dicle Sener Okur,1 Caner Yuruyen,2 Ozge Gungor,2 ...

Virus tricks the immune system into ignoring bacterial infections    Nature.com The finding could explain why the body tolerates some microbes ― and lead to better treatments for chronic infections.

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

This Week in Science    Science Magazine A herd of blue wildebeest, Connochaetes taurinus, graze in the Maasai Mara National Reserve in Kenya. PHOTO: IMAGEBROKER/ALAMY STOCK PHOTO.

Final Results    Nasdaq Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress. Focus on.

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Virus tricks the immune system into ignoring bacterial infections    Nature.com The finding could explain why the body tolerates some microbes ― and lead to better treatments for chronic infections.

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Aridis Pharmaceuticals poised for readout of top-line data for its flagship AR-105 treatment in 3Q    Proactive Investors USA & Canada Aridis Pharmaceuticals Inc (NASDAQ:ARDS) - AR-105 is a treatment for ventilator-associated pneumonia caused by a variety of Pseudomonas aeruginosa, ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal    Nasdaq GAITHERSBURG, Md., March 28, 2019-- OpGen, Inc. announced today that data supporting prediction of antibiotic resistance using the company' s.

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Synspira Therapeutics Announces Appointment of Robert Gallotto as President and Chief Executive Officer    PRNewswire Synspira's lead product targeting cystic fibrosis and other pulmonary diseases, SNSP113, to enter Phase 2 Clinical Trials in Second Half of 2019 - ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Bacteria partners with virus to cause chronic wounds    Science Daily A common bacterial pathogen called Pseudomonas aeruginosa produces a virus that substantially increases the pathogen's ability to infect us, according to a ...

Virus tricks the immune system into ignoring bacterial infections    Nature.com The finding could explain why the body tolerates some microbes ― and lead to better treatments for chronic infections.

Virus tricks the immune system into ignoring bacterial infections    Nature.com The finding could explain why the body tolerates some microbes ― and lead to better treatments for chronic infections.

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal    Nasdaq GAITHERSBURG, Md., March 28, 2019-- OpGen, Inc. announced today that data supporting prediction of antibiotic resistance using the company' s.

Form 10-K Entasis Therapeutics For: Dec 31    StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Table of Contents. UNITED STATES.

Virus tricks the immune system into ignoring bacterial infections    Nature.com The finding could explain why the body tolerates some microbes ― and lead to better treatments for chronic infections.

Targeting Bacteria Cell-Wall Elements Can Help Fight P. Aeruginosa    Cystic Fibrosis News Today A new research study showed that targeting bacteria cell wall elements may help activate the natural immune defenses against P. aeruginosa infection.